Gilead teams up with Terray for AI-powered drug discovery, leveraging Terray’s tNova platform to accelerate the development ...

Palatin Technologies has announced topline results for the phase 2b Breakout study, which evaluated the effects of bremelanotide in patients with type 2 diabetic nephropathy. This condition is a ...

The acquisition of Nimble Therapeutics will grant AbbVie access to a pipeline of oral peptide drugs for the treatment of immune diseases including psoriasis and inflammatory bowel disease AbbVie and ...

Founded by a team of scientists and healthcare specialists in 2021, Nintx harnesses compounds from Brazil’s world-famous plant ecosystems to develop treatments for complex, multifactorial diseases ...

Noema Pharma has announced an extension of its series B financing round, bringing the total raised up to $147 million (CHF 130 million). The round extension has seen venture capital firm EQT Life ...

Is the key to curing the world’s most challenging diseases hidden in unlocking the power of fragmented biological data? The company creator General Inception (GI) has acquired Enable Medicine to pool ...

Pharma company, AbbVie, reports that its D1/D5 partial agonist, tavapadon, has met the primary and secondary endpoints in a pivotal Phase 3 trial. The trial, called TEMPO-2, evaluated the ...

Shortly after acquiring a manufacturing site in Wisconsin, Eli Lilly intends to expand it to boost its production of injectable products, including diabetes and obesity drugs Mounjaro and Zepbound.

The pharma arm of Mitsubishi Chemical Group has launched a collaboration with US-based Dewpoint Therapeutics to co-develop a preclinical-stage treatment for the neurological condition amyotrophic ...

Investment in radiopharmaceuticals is ramping up as big pharma shows a growing appetite for this promising drug modality. Radiopharmaceuticals see radioactive isotopes being delivered into a target, ...